These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19017594)

  • 1. Needed: new and better tools to combat latent tuberculosis infection.
    Blumberg HM
    Ann Intern Med; 2008 Nov; 149(10):761-3. PubMed ID: 19017594
    [No Abstract]   [Full Text] [Related]  

  • 2. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
    Reichman LB; Lardizabal A; Hayden CH
    Am J Respir Crit Care Med; 2004 Oct; 170(8):832-5. PubMed ID: 15297274
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antitubercular drug-induced liver injuries].
    Guo Y; Cui D
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):308-9. PubMed ID: 11326960
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
    Menzies D; Long R; Trajman A; Dion MJ; Yang J; Al Jahdali H; Memish Z; Khan K; Gardam M; Hoeppner V; Benedetti A; Schwartzman K
    Ann Intern Med; 2008 Nov; 149(10):689-97. PubMed ID: 19017587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
    Duarte R; Carvalho A; Correia A
    Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
    Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
    Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts.
    Young H; Wessolossky M; Ellis J; Kaminski M; Daly JS
    Clin Infect Dis; 2009 Aug; 49(3):424-7. PubMed ID: 19548835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
    Ena J; Valls V
    Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    JAMA; 2002 Dec; 288(23):2967. PubMed ID: 12492097
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolerability of rifampin monotherapy for latent tuberculosis infection in children.
    Daskalaki I; Byun J; Dogbey MC; Tolbert-Warren C; Watson BM
    Pediatr Infect Dis J; 2011 Nov; 30(11):1014-5. PubMed ID: 21997666
    [No Abstract]   [Full Text] [Related]  

  • 12. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
    Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antituberculosis agents.
    Goldberger MJ
    Med Clin North Am; 1988 May; 72(3):661-8. PubMed ID: 3280912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present chemotherapy for tuberculosis.
    Dutt AK; Stead WW
    J Infect Dis; 1982 Nov; 146(5):698-704. PubMed ID: 6813386
    [No Abstract]   [Full Text] [Related]  

  • 15. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 17. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
    Ziakas PD; Mylonakis E
    Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Addisonian crises induced by rifampicin].
    Campos-Varela I; Perich-Jackson D; Ferrer-Sancho J
    Arch Bronconeumol; 2006 Jul; 42(7):376. PubMed ID: 16945269
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.